Sage shares surge as depression drug succeeds in mid-stage trial

Published 8y ago

(Reuters) – Drug developer Sage Therapeutics Inc’s shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial. Sage’s shares were up 73 percent at $159, on tr... More »